Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Kazuki, Yasuhiro ^a   Yakura, Yuwna ^a   Abe, Satoshi ^a   Osaki, Mitsuhiko ^a   Kajitani, Naoyo ^a   Kazuki, Kanako ^a   Takehara, Shoko ^a   Honma, Kazuhisa ^a   Suemori, Hirofumi ^b   Yamazaki, Satoshi ^c   Sakuma, Tetsushi ^d   Toki, Tsutomu ^e   Shimizu, Ritsuko ^f   Nakauchi, Hiromitsu ^c   Yamamoto, Takashi ^d   Oshimura, Mitsuo ^a  

^a TOTTORI UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d HIROSHIMA UNIVERSITY   (Japan)

^e HIROSAKI UNIVERSITY   (Japan)

^f TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GATA1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR GATA 1;

ANIMAL; CELL CULTURE; CHROMOSOME 21; DOWN SYNDROME; GENETIC ENGINEERING; GENETIC TRANSFECTION; GENETICS; HEMATOPOIESIS; HUMAN; HUMAN GENOME; LEUKEMOID REACTION; MOUSE; PATHOPHYSIOLOGY; PHYSIOLOGY; PLURIPOTENT STEM CELL;

ANIMALS; CELLS, CULTURED; CHROMOSOMES, HUMAN, PAIR 21; DOWN SYNDROME; GATA1 TRANSCRIPTION FACTOR; GENETIC ENGINEERING; GENOME, HUMAN; HEMATOPOIESIS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUKEMOID REACTION; MICE; TRANSFECTION;

EID: 84906689921     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep06136     Document Type: Article

References (30)

1. Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A. & Deutsch, S. Chromosome 21 and down syndrome: from genomics to pathophysiology. Nat Rev Genet 5, 725-738 (2004).
2. Lange, B. The management of neoplastic disorders of haematopoiesis in children with Down's syndrome. Br J Haematol 110, 512-524 (2000).
3. Massey,G.V. et al.Aprospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood 107, 4606-4613 (2006).
4. Malinge, S., Izraeli, S. & Crispino, J. D. Insights into themanifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 113, 2619-2628 (2009).
5. Gamis, A. S. et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood 118, 6752-6759; quiz 6996 (2011).
6. Wechsler, J. et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32, 148-152 (2002).
7. Xu, G. et al. Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102, 2960-2968 (2003).
8. Ahmed, M. et al. Natural history of GATA1 mutations in Down syndrome. Blood 103, 2480-2489 (2004).
9. Yoshida, K. et al. The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 45, 1293-1299 (2013).
10. Thomson, J. A. et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
11. Takahashi, K. & Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126, 663-676 (2006).
12. Song, H., Chung, S. K.&Xu, Y. Modeling disease in human ESCs using an efficient BAC-based homologous recombination system. Cell Stem Cell 6, 80-89 (2010).
13. Soldner, F. et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146, 318-331 (2011).
14. Ding, Q. et al. A TALEN genome-editing system for generating human stem cellbased disease models. Cell Stem Cell 12, 238-251 (2013).
15. Maclean, G. A. et al. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A 109, 17567-17572 (2012).
16. Chou, S. T. et al. Trisomy 21-associated defects in human primitive hematopoiesis revealed through induced pluripotent stem cells. Proc Natl Acad Sci U S A 109, 17573-17578 (2012).
17. Li, L. B. et al. Trisomy correction in Down syndrome induced pluripotent stem cells. Cell Stem Cell 11, 615-619 (2012).
18. Meaburn, K. J., Parris, C. N. & Bridger, J. M. The manipulation of chromosomes by mankind: the uses of microcell-mediated chromosome transfer. Chromosoma 114, 263-274 (2005).
19. Inoue, J. et al. Construction of 700 human/mouse A9 monochromosomal hybrids and analysis of imprinted genes on human chromosome 6. J Hum Genet 46, 137-145 (2001).
20. Shinohara, T. et al. Mice containing a human chromosome 21 model behavioral impairment and cardiac anomalies of Down's syndrome. Hum Mol Genet 10, 1163-1175 (2001).
21. O'Doherty, A. et al. An aneuploid mouse strain carrying human chromosome 21 with Down syndrome phenotypes. Science 309, 2033-2037 (2005).
22. Gaj, T., Gersbach, C. A. & Barbas, C. F. 3rd ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol 31, 397-405 (2013).
23. Terui, K. et al. Expression of transcription factors during megakaryocytic differentiation of CD34+ cells from human cord blood induced by thrombopoietin. Tohoku J Exp Med 192, 259-273 (2000).
24. Hollanda, L. M. et al. An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 38, 807-812 (2006).
25. Sankaran, V. G. et al. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest 122, 2439-2443 (2012).
26. Kuroiwa, Y. et al.Manipulation of humanminichromosomes to carry greater than megabase-sized chromosome inserts. Nat Biotechnol 18, 1086-1090 (2000).
27. Kazuki, Y. et al. Refined human artificial chromosome vectors for gene therapy and animal transgenesis. Gene Ther 18, 384-393 (2011).
28. Kazuki, Y. & Oshimura, M. Human artificial chromosomes for gene delivery and the development of animal models. Mol Ther 19, 1591-1601 (2011).
29. Hasegawa, K., Fujioka, T., Nakamura, Y., Nakatsuji, N. & Suemori, H. A method for the selection of human embryonic stem cell sublines with high replating efficiency after single-cell dissociation. Stem Cells 24, 2649-2660 (2006).
30. Takayama, N. et al. Generation of functional platelets from human embryonic stem cells in vitro via ES-sacs, VEGF-promoted structures that concentrate hematopoietic progenitors. Blood 111, 5298-5306 (2008).